清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer

多西紫杉醇 医学 彭布罗利珠单抗 肿瘤科 肺癌 内科学 化疗 癌症 临床终点 临床试验 免疫疗法
作者
Óscar Arrieta,Feliciano Barrón,Laura Alejandra Ramírez-Tirado,Zyanya Lucía Zatarain-Barrón,Andrés F. Cardona,Diego A. Díaz-García,Masao Yamamoto Ramos,Beatriz Mota-Vega,Amir Carmona,Marco Polo Peralta Álvarez,Yolanda Bautista,Fernando Aldaco,Raquel Gerson,Christian Rolfo,Rafael Rosell
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:6 (6): 856-856 被引量:153
标识
DOI:10.1001/jamaoncol.2020.0409
摘要

Importance: Because of socioeconomic factors, many patients with advanced non-small cell lung cancer (NSCLC) do not receive immunotherapy in the first-line setting. It is unknown if the combination of immunotherapy with chemotherapy can provide clinical benefits in immunotherapy-naive patients with disease progression after treatment with platinum-based chemotherapy. Objective: To evaluate the safety and efficacy of the combination of pembrolizumab plus docetaxel in patients with previously treated advanced NSCLC following platinum-based chemotherapy regardless of EGFR variants or programmed cell death ligand 1 status. Design, Setting, and Participants: The Pembrolizumab Plus Docetaxel for Advanced Non-Small Cell Lung Cancer (PROLUNG) trial randomized 78 patients with histologically confirmed advanced NSCLC in a 1:1 ratio to receive either pembrolizumab plus docetaxel or docetaxel alone from December 2016 through May 2019. Interventions: The experimental arm received docetaxel on day 1 (75 mg/m2) plus pembrolizumab on day 8 (200 mg) every 3 weeks for up to 6 cycles followed by pembrolizumab maintenance until progression or unacceptable toxic effects. The control arm received docetaxel monotherapy. Main Outcomes and Measures: The primary end point was overall response rate (ORR). Secondary end points included progression-free survival (PFS), overall survival, and safety. Results: Among 78 recruited patients, 32 (41%) were men, 34 (44%) were never smokers, and 25 (32%) had an EGFR/ALK alteration. Forty patients were allocated to receive pembrolizumab plus docetaxel, and 38 were allocated to receive docetaxel. A statistically significant difference in ORR, assessed by an independent reviewer, was found in patients receiving pembrolizumab plus docetaxel vs patients receiving docetaxel (42.5% vs 15.8%; odds ratio, 3.94; 95% CI, 1.34-11.54; P = .01). Patients without EGFR variations had a considerable difference in ORR of 35.7% vs 12.0% (P = .06), whereas patients with EGFR variations had an ORR of 58.3% vs 23.1% (P = .14). Overall, PFS was longer in patients who received pembrolizumab plus docetaxel (9.5 months; 95% CI, 4.2-not reached) than in patients who received docetaxel (3.9 months; 95% CI, 3.2-5.7) (hazard ratio, 0.24; 95% CI, 0.13-0.46; P < .001). For patients without variations, PFS was 9.5 months (95% CI, 3.9-not reached) vs 4.1 months (95% CI, 3.5-5.3) (P < .001), whereas in patients with EGFR variations, PFS was 6.8 months (95% CI, 6.2-not reached) vs 3.5 months (95% CI, 2.3-6.2) (P = .04). In terms of safety, 23% (9 of 40) vs 5% (2 of 38) of patients experienced grade 1 to 2 pneumonitis in the pembrolizumab plus docetaxel and docetaxel arms, respectively (P = .03), while 28% (11 of 40) vs 3% (1 of 38) experienced any-grade hypothyroidism (P = .002). No new safety signals were identified. Conclusions and Relevance: In this phase 2 study, the combination of pembrolizumab plus docetaxel was well tolerated and substantially improved ORR and PFS in patients with advanced NSCLC who had previous progression after platinum-based chemotherapy, including NSCLC with EGFR variations. Trial Registration: ClinicalTrials.gov Identifier: NCT02574598.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Lan完成签到 ,获得积分10
9秒前
17秒前
冷傲的夜白完成签到,获得积分10
18秒前
JUN完成签到,获得积分10
25秒前
29秒前
瞿人雄完成签到,获得积分10
29秒前
007发布了新的文献求助30
33秒前
葵辰完成签到 ,获得积分10
34秒前
35秒前
35秒前
35秒前
39秒前
maprang完成签到,获得积分10
59秒前
李爱国的应助被levosimendan采纳,获得10
1分钟前
木齐Jay完成签到,获得积分10
1分钟前
无花果的应助被粉色紫米粥采纳,获得10
1分钟前
007完成签到,获得积分10
2分钟前
2分钟前
领导范儿的应助被xun采纳,获得10
2分钟前
悲凉的丝完成签到,获得积分10
2分钟前
2分钟前
汉堡包的应助被科研通管家采纳,获得10
2分钟前
2分钟前
2分钟前
2分钟前
欠欠发布了新的文献求助10
2分钟前
明月朗晴完成签到 ,获得积分10
2分钟前
drkyy完成签到,获得积分10
2分钟前
天天快乐的应助被whc采纳,获得10
2分钟前
2分钟前
2分钟前
levosimendan发布了新的文献求助10
2分钟前
风趣的夏波完成签到,获得积分10
3分钟前
whc发布了新的文献求助10
3分钟前
oleskarabach完成签到,获得积分20
3分钟前
3分钟前
xun发布了新的文献求助10
3分钟前
3分钟前
酷波er的应助被xun采纳,获得10
3分钟前
levosimendan发布了新的文献求助10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190159
求助须知:如何正确求助?哪些是违规求助? 9577264
关于积分的说明 21852314
捐赠科研通 7788621
什么是DOI,文献DOI怎么找? 3436279
关于科研通互助平台的介绍 2560058
邀请新用户注册赠送积分活动 2482880